Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation

  • Martínez Corral, Inés
  • Zhang, Yan
  • Petkova, Milena
  • Ortsäter, Henrik
  • Sjöberg, Sofie
  • Castillo, Sandra D.
  • Brouillard, Pascal
  • Libbrecht, Louis
  • Saur, Dieter
  • Graupera i Garcia-Milà, Mariona
  • Alitalo, Kari
  • Boon, Laurence
  • Vikkula, Miikka
  • Mäkinen, Taija
Lymphatic malformations (LMs) are debilitating vascular anomalies presenting with large cysts (macrocystic) or lesions that infiltrate tissues (microcystic). Cellular mechanisms underlying LM pathology are poorly understood. Here we show that the somatic PIK3CAH1047R mutation, resulting in constitutive activation of the p110α PI3K, underlies both macrocystic and microcystic LMs in human. Using a mouse model of PIK3CAH1047R-driven LM, we demonstrate that both types of malformations arise due to lymphatic endothelial cell (LEC)-autonomous defects, with the developmental timing of p110α activation determining the LM subtype. In the postnatal vasculature, PIK3CAH1047R promotes LEC migration and lymphatic hypersprouting, leading to microcystic LMs that grow progressively in a vascular endothelial growth factor C (VEGF-C)-dependent manner. Combined inhibition of VEGF-C and the PI3K downstream target mTOR using Rapamycin, but neither treatment alone, promotes regression of lesions. The best therapeutic outcome for LM is thus achieved by co-inhibition of the upstream VEGF-C/VEGFR3 and the downstream PI3K/mTOR pathways.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice

  • Maresch, Roman
  • Varela, Ignacio
  • Rad, Roland
Maresch, Roman et al., Mouse transgenesis has provided fundamental insights into pancreatic cancer, but is limited by the long duration of allele/model generation. Here we show transfection-based multiplexed delivery of CRISPR/Cas9 to the pancreas of adult mice, allowing simultaneous editing of multiple gene sets in individual cells. We use the method to induce pancreatic cancer and exploit CRISPR/Cas9 mutational signatures for phylogenetic tracking of metastatic disease. Our results demonstrate that CRISPR/Cas9-multiplexing enables key applications, such as combinatorial gene-network analysis, in vivo synthetic lethality screening and chromosome engineering. Negative-selection screening in the pancreas using multiplexed-CRISPR/Cas9 confirms the vulnerability of pancreatic cells to Brca2-inactivation in a Kras-mutant context. We also demonstrate modelling of chromosomal deletions and targeted somatic engineering of inter-chromosomal translocations, offering multifaceted opportunities to study complex structural variation, a hallmark of pancreatic cancer. The low-frequency mosaic pattern of transfection-based CRISPR/Cas9 delivery faithfully recapitulates the stochastic nature of human tumorigenesis, supporting wide applicability for biological/preclinical research., The work was supported by the German Cancer Consortium Joint Funding Program, the Helmholtz Gemeinschaft (PCCC Consortium) and the European Research Council (ERC CoG No. 648521)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes

  • Mueller, Sebastian
  • Engleitner, Thomas
  • Maresch, Roman
  • Zukowska, Magdalena
  • Lange, Sebastian
  • Kaltenbacher, Thorsten
  • Konukiewitz, Björn
  • Öllinger, Rupert
  • Zwiebel, Maximilian
  • Strong, Alex
  • Yen, Hsi-Yu.
  • Banerjee, Pradeep
  • Louzada, S.
  • Fu, Beiyuan
  • Seidler, Barbara
  • Götzfried, Juliana
  • Schuck, Kathleen
  • Hassan, Zonera
  • Arbeiter, Amdreas
  • Schönhuber, Nina
  • Klein, Sabine
  • Veltkamp, Christian
  • Friedrich, Mathias
  • Rad, Lena
  • Barenboim, Maxim
  • Ziegenhain, Christoph
  • Hess, Julia
  • Dovey, Oliver M.
  • Eser, Stefan
  • Parekh, Swati
  • Constantino-Casas, Fernando
  • Rosa, Jorge de la
  • Sierra, Marta I.
  • Fraga, Mario F.
  • Mayerle, Julia
  • Klöppel, Günter
  • Cadiñanos, Juan
  • Liu, Pentao
  • Vassiliou, George S.
  • Weichert, Wilko
  • Steiger, Katja
  • Enard, Wolfgang
  • Schmid, Roland M.
  • Yang, Fengtang
  • Unger, Kristian
  • Schneider, Günter
  • Varela, Ignacio
  • Bradley, Allan
  • Saur, Dieter
  • Rad, Roland
The poor correlation of mutational landscapes with phenotypes limits our understanding of the pathogenesis and metastasis of pancreatic ductal adenocarcinoma (PDAC). Here we show that oncogenic dosage-variation has a critical role in PDAC biology and phenotypic diversification. We find an increase in gene dosage of mutant KRAS in human PDAC precursors, which drives both early tumorigenesis and metastasis and thus rationalizes early PDAC dissemination. To overcome the limitations posed to gene dosage studies by the stromal richness of PDAC, we have developed large cell culture resources of metastatic mouse PDAC. Integration of cell culture genomes, transcriptomes and tumour phenotypes with functional studies and human data reveals additional widespread effects of oncogenic dosage variation on cell morphology and plasticity, histopathology and clinical outcome, with the highest Kras MUT levels underlying aggressive undifferentiated phenotypes. We also identify alternative oncogenic gains (Myc, Yap1 or Nfkb2), which collaborate with heterozygous Kras MUT in driving tumorigenesis, but have lower metastatic potential. Mechanistically, different oncogenic gains and dosages evolve along distinct evolutionary routes, licensed by defined allelic states and/or combinations of hallmark tumour suppressor alterations (Cdkn2a, Trp53, Tgfβ-pathway). Thus, evolutionary constraints and contingencies direct oncogenic dosage gain and variation along defined routes to drive the early progression of PDAC and shape its downstream biology. Our study uncovers universal principles of Ras-driven oncogenesis that have potential relevance beyond pancreatic cancer., The work was supported by the German Cancer Consortium Joint Funding Program, the Helmholtz Gemeinschaft (PCCC Consortium), the German Research Foundation (SFB1243; A13/A14) and the European Research Council (ERC CoG number 648521)., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation

  • Martínez Corral, Inés
  • Zhang, Yan
  • Petkova, Milena
  • Ortsäter, Henrik
  • Sjöberg, Sofie
  • Castillo, Sandra D.
  • Brouillard, Pascal
  • Libbrecht, Louis
  • Saur, Dieter
  • Graupera i Garcia-Milà, Mariona
  • Alitalo, Kari
  • Boon, Laurence
  • Vikkula, Miikka
  • Mäkinen, Taija
Lymphatic malformations (LMs) are debilitating vascular anomalies presenting with large cysts (macrocystic) or lesions that infiltrate tissues (microcystic). Cellular mechanisms underlying LM pathology are poorly understood. Here we show that the somatic PIK3CAH1047R mutation, resulting in constitutive activation of the p110α PI3K, underlies both macrocystic and microcystic LMs in human. Using a mouse model of PIK3CAH1047R-driven LM, we demonstrate that both types of malformations arise due to lymphatic endothelial cell (LEC)-autonomous defects, with the developmental timing of p110α activation determining the LM subtype. In the postnatal vasculature, PIK3CAH1047R promotes LEC migration and lymphatic hypersprouting, leading to microcystic LMs that grow progressively in a vascular endothelial growth factor C (VEGF-C)-dependent manner. Combined inhibition of VEGF-C and the PI3K downstream target mTOR using Rapamycin, but neither treatment alone, promotes regression of lesions. The best therapeutic outcome for LM is thus achieved by co-inhibition of the upstream VEGF-C/VEGFR3 and the downstream PI3K/mTOR pathways.